CFChieh-Lin Fu

Chieh-Lin Fu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chieh-Lin Fu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comorbidity burden is a major independent prognostic factor in Waldenström Macroglobulinemia: A national cancer database retrospective study

    by Gaelle C. Haddad, Aaron Sidhu, Hong Liang, Yehuda Galili, Chieh-Lin Fu, Chakra P. Chaulagain

  • Serial VAF Kinetics Reveal Dynamic Clonal Evolution Associated With Progression in Clonal Cytopenia of Undetermined Significance

    by Zohre Sadeghian, Mark Jinan Chen, Kirill A. Lyapichev, Chieh‐Lin Fu, Chakra Chaulagain, Maria Julia Diacovo, David S. Bosler, Amir Behdad

    Background: Clonal cytopenia of undetermined significance (CCUS) is a premalignant condition characterized by persistent cytopenias with somatic mutations but no morphologic evidence of overt myeloid neoplasia. While CCUS confers an elevated risk of progression to myeloid malignancies, the timing and biology of this transformation remain unpredictable. We hypothesized that the type of mutated gene and tracking clonal expansion over time via serial variant allele frequency (VAF) measurements may uncover early evolutionary signatures of malignant progression. Design: We retrospectively analyzed 55 CCUS patients who underwent serial next‐generation sequencing (NGS) testing. Patients were stratified by their final clinical course at the time of this study as non‐progressor ( n = 26) or progressor ( n = 29). Baseline clinicopathologic variables, mutation burden, and the presence of ≥ 1 high‐risk mutation, which was defined in prior studies as SF3B1 , SRSF2 , ZRSR2 , JAK2 , TP53 , RUNX1 , FLT3 , IDH1 , and IDH2 , were compared between groups. The maximum annualized VAF slope across all tracked mutations was used as the primary dynamic clonal expansion metric. Baseline risk was assessed using the Clonal Hematopoiesis Risk Score (CHRS), and maximum VAF slope was evaluated across CHRS categories to determine whether serial clonal kinetics provided additional prognostic value beyond baseline risk stratification. Results: Compared with non‐progressors, progressors had a higher baseline mutation burden ( p < 0.01), more frequently harbored ≥ 1 high‐risk mutation at baseline ( p < 0.01), and also more acquired new mutations during follow‐up ( p < 0.01). Across longitudinally tracked mutations, progressor‐associated clones more frequently demonstrated positive annualized VAF slopes, particularly involving RUNX1 (12.70%/year), STAG2 (13.09%/year), ASXL1 (6.44%/year), SRSF2 (4.29%/year), and U2AF1 (8.21%/year). Maximum annualized VAF slope correlated with CHRS risk category but also identified increased clonal expansion among progressors within the non‐high CHRS subgroup ( p = 0.006), suggesting added dynamic prognostic value beyond static baseline risk classification. Conclusion: Serial VAF kinetics are helpful in predicting progression and complement baseline clinicopathologic features and CHRS risk stratification in CCUS. Expanding VAF trajectories, particularly involving RUNX1 , spliceosome genes, and cohesin‐related genes, may reflect biologically active clonal evolution toward progression to myeloid neoplasm, whereas stable or declining VAFs were more often observed in stable CCUS. These findings support that longitudinal VAF monitoring could be a practical dynamic approach to identify patients who require closer surveillance or repeat marrow evaluation.

  • Open Access

    Utilization of Next-Generation Sequencing (NGS) in Unexplained Cytopenia

    by Zohre Sadeghian, Kirill A. Lyapichev, Mark J. Chen, Maria J. Diacovo, Chakra Chaulagain, Chieh-Lin Fu, David S. Bosler, Amir Behdad

  • Open Access

    Comparative Outcomes Between Black and White Patients With Early‐Stage Diffuse Large B‐Cell Lymphoma

    by María Herrán, Sindu Iska, Hong Liang, Ludovic Saba, Chakra P. Chaulagain, Chieh‐Lin Fu

    Introduction: Determinants of survival in DLBCL stage I–IV collectively have reported Black patients and advanced stage to have worse outcomes on multivariate analysis. As advanced stage is a factor in outcome, available data have not focused on early‐stage DLBCL to evaluate the impact of race and SES on outcome. To address this research gap, the study aims to examine and compare the characteristics and the determinants of survival between US Black and White patients with early‐stage (I–II) DLBCL. Methods: A retrospective NCDB analysis of early‐stage DLBCL patients was conducted, comparing sociodemographic, clinical, and treatment factors between Black and White groups. Chi‐square tests assessed differences. Multivariate Cox regression identified survival predictors. Matched patient pairs were analyzed using Cox models with robust variance, and Kaplan–Meier curves evaluated survival outcomes by race. Results: 81,430 early‐stage DLBCL patients diagnosed between 2004 and 2017 included 5,709 Black and 75,721 White patients. Multivariate analysis showed higher mortality risk for males (HR 1.09), aged ≥ 60 (HR 2.04), ≥ 2 comorbidities (HR 1.92), B symptoms (HR 1.23), HIV infection (HR 1.59), and lower income (HR 1.18) (all p < 0.0001). Notably, survival rates between Black and White patients were not significantly different (HR 0.98, p = 0.5263). Conclusion: Black patients have been reported to have worse survival for DLBCL, considering all stages collectively. The remarkable finding of our study was that despite disparities in socioclinical determinants, no overall survival difference was observed between Black and White patients with early‐stage DLBCL. We suggest that the similar survival in early‐stage DLBCL for Black and White patients is primarily overcome by the favorable remission rate of early‐stage DLBCL and accessibility to conventional chemoimmunotherapy. We also imply that the survival disparity between Black and White patients in DLBCL is more likely to be the impact of socioclinical determinants on advanced stage III/IV DLBCL.

  • Open Access

    A 24-year-old man with severe hemolytic anemia and variable Coombs test results

    by Sindu Iska, María Herrán, You Li, Maria Teresa Bejarano, Chakra P. Chaulagain, Chieh-Lin Fu


  • An Atypical relapsing follicular lymphoma to composite Hodgkin’s lymphoma

    by Sandra Abadir, Sindu Iska, Silvia Tse Bunting, Chieh-Lin Fu

    Composite lymphoma is defined as two or more lymphomas with distinct morphological and immunophenotypical characteristics synchronously diagnosed at the same anatomical site. Composite lymphoma is rare, and the most common combination is follicular lymphoma (FL) associated with diffuse large B cell lymphoma, followed by FL associated with classic Hodgkin’s lymphoma (HL). Histologically, composite lymphomas display a mixed pattern or distinct zonal distribution of each lymphoma component. Composite lymphoma poses a diagnostic challenge, especially when two lymphoma components are mixed in the same lymph node. Here, we report a case of composite HL and FL 11 years after initial and repeat biopsies consistent with FL in a man in his 70s emphasising the importance of repeat biopsy in lymphoma diagnosis.


  • Open Access

    Determinants of Overall Survival (OS) of Waldenstrom Macroglobulinemia (WM): A National Cancer Database (NCDB) Analysis of over 14,000 Patients Treated between Years 2004 and 2017

    by Chakra P Chaulagain, Kevin Landau, Hong Liang, Chieh-Lin Fu

    Introduction: Real world outcome data for Waldenstrom Macroglobulinemia (WM) is limited due to relatively rare and indolent nature of this B cell Non-Hodgkin ly

  • Open Access

    Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma

    by Chakra P Chaulagain, Maroun Bou Zerdan, Jack Khouri, Beth M. Faiman, Faiz Anwer, Chieh-Lin Fu, Jason Valent

    The COVID-19 (SARS-CoV-2) pandemic has led to unprecedented challenges in providing cancer care to patients all over the world. Compared to the general populati

  • Determinants of overall survival (OS) of primary plasma cell leukemia (pPCL): A National Cancer Database (NCDB) analysis of years 2004 to 2009.

    by Kevin Scott Landau, Kelsey Lynn Mowery, Hong Liang, Chieh Lin Fu, Chakra Pani Chaulagain

    8066 Background: Outcome data for pPCL is limited due to the rare & aggressive nature of the disease. In this retrospective analysis, we utilized NCDB to identify factors contributing to 1 & 5-year OS of pPCL patients treated at CoC-accredited facilities across USA. Methods: Using the NCDB, we identified N= 325 pPCL patients diagnosed between 2004-2009 after excluding entries missing relevant values. Univariate analysis was used to summarize & assess the potential survival factors individually & multivariate Cox regression analysis with backward elimination (using significance level of p<0.05) was utilized to identify the independent survival factors. Kaplan-Meier (KM) survival curves of patient cohort were also produced. SAS version 9.4 was used to analyze the data. Results: Multivariate Cox regression analysis with backward elimination method revealed that there were 4 significant independent survival factors including sex, Charlson-Deyo Comorbidity Index (CCI), facility type, and insurance, while age & year-of-diagnosis were not independent survival factors (Table). Male patients were more likely to die compared to female patients (HR=1.40, p=0.005); patients with CCI ≥1 had higher chance to suffer death compared to patients with CCI= 0 (HR=1.52, p=0.002); patients not treated at an academic center (AC) had lower survival compared to those treated at ACs (HR=1.35, p=0.001); and patients without private insurance (PI) were more likely to suffer death compared to those with PI (HR=1.54, p=0.001). The 1 & 5-year survival rates for whole cohort were 51.3% (95%CI: 45.8%-56.8%), and 18.9% (95%CI: 14.6%-23.2%) using KM estimate, respectively. Only 6/325 =1.8% patients underwent autologous hematopoietic stem cell transplant (HSCT). Detailed analysis will be presented. Conclusions: In this large analysis of pPCL patients, we identified that being female, having less comorbidities, getting treatment at ACs, and having PI had significantly greater OS. Overall, pPCL is associated with low survival rates both at 1 & 5-years and HSCT may be enormously under-utilized for pPCL patients in the real world setting.